Kinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular Disease

businesswire

Kinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular Disease – NEWSnet – News… as it used to be

More Press Releases

June 22, 2026

ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm

June 22, 2026

Oliveda International, Inc. Announces Launch of World’s First Waterless Skincare Line for Babies and Moms Based on the Olive Tree

June 22, 2026

Culpeper Launches “Road to Revolution” Heritage Storytelling Campaign for America 250 Commemoration

June 22, 2026

Kinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular Disease

ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm

Oliveda International, Inc. Announces Launch of World’s First Waterless Skincare Line for Babies and Moms Based on the Olive Tree

Culpeper Launches “Road to Revolution” Heritage Storytelling Campaign for America 250 Commemoration

DANDY® CELERY SNACK PACKS NAMED SELECTED AS A GOOD HOUSEKEEPING 2026 SNACK AWARDS WINNER